While they do show some promise, the effects may not all apply to humans
The FDA-approved prescribing information states that tesamorelin is not indicated for weight-loss management because it has a weight-neutral effect. In the Phase 3 studies, total body weight changed very little even though the tesamorelin groups demonstrated reductions in: Visceral adipose tissue Waist circumference Trunk fat At the same time, modest increases in lean body mass were reported
Express Scripts has the highest formulary inclusion rate but the lowest first-submission approval rate
Record the date, dose, and injection site in a log
For comprehensive information about Ozempic treatment, see our complete guide to Ozempic for weight loss
This is a critical development because it may help prevent metabolic adaptation, the common process where the body slows its energy expenditure during weight loss to preserve fat stores